Therapie der Akromegalie (aktualisiert/ rezertifiziert)

CME-Fortbildung: Therapie der Akromegalie (aktualisiert/ rezertifiziert)

Referenzen

1. van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25:426-457.
2. Melmed S. Acromegaly. In: Melmed S, ed. The pituitary. Cambridge: Blackwell, 1995; 413-442.
3. Schopohl J. Akromegalie. In: Stalla GK, ed. Therapieleitfaden Hypophysenerkrankungen. Bremen: Uni-Med Verlag, 2004; 49-56.
4. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999; 2:29-41.
5. Stewart PM. Acromegaly databases - time for European unification. Eur J Endocrinol 2004; 151:431-432.
6. Pagotto U, Theodoropoulou M, Renner U. Epidemiologie, Klassifikation und Pathogenese von Hypophysenadenomen. In: Stalla GK, ed. Therapieleitfaden Hypophysenerkrankungen. Bremen: Uni-Med Verlag, 2004; 28-41.
7. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 2003; 112:1603-1618.
8. Losa M, Schopohl J, von Werder K. Ectopic secretion of growth hormone-releasing hormone in man. J Endocrinol Invest 1993; 16:69-81.
9. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25:102-152.
10. Corville C, Mason MR. The heart in acromegaly. Arch Intern Med 1938; 61:704-713.
11. Growth Hormone Research Society, The Pituitary Society. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and The Pituitary Society. J Clin Endocrinol Metab 2004; 89:3099-3102.
12. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992; 21:669-692.
13. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005; 152:379-387.
14. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002; 87:4054-4058.
15. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005; 90:4405-4410.
16. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002; 87:4554-4563.
17. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006; 91:1397-1403.
18. Muller AF, Van Der Lely AJ. Pharmacological therapy for acromegaly: a critical review. Drugs 2004; 64:1817-1838.
19. Ezzat S. Pharmacological approach to the treatment of acromegaly. Neurosurg Focus 2004; 16:E3.
20. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005; 153:737-740.
21. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005; 90:4465-4473.
22. Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005; 152:569-574.
23. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342:1171-1177.
24. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358:1754-1759.
25. German Pegvisomant Observational Study. 2005.
26. Biering H, Saller B, Bauditz J, et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 2006; 154:213-220.
27. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005; 365:1644-1646.
28. Biermasz NR, Romijn JA, Pereira AM, Roelfsema F. Current pharmacotherapy for acromegaly: a review. Expert Opin Pharmacother 2005; 6:2393-2405.
29. Kajiwara K, Saito K, Yoshikawa K, et al. Image-guided stereotactic radiosurgery with the CyberKnife for pituitary adenomas. Minim Invasive Neurosurg 2005; 48:91-96.
30. Engenhart-Cabillic R, Kocher M, Muller RP, et al. Leitlinien zur Strahlentherapie von Hypophysenadenomen. Dtsch Med Wochenschr 1999; 124:1148-1152.
31. Petersenn S, Lüdecke DK, Fahlbusch R, et al. Therapie von Hypophysentumoren. Dt Arztebl 2006; 103:A474-481.
32. American Association of Clinical Endocrinologists. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract 2004; 10:213-225.
33. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89:1613-1617.
34. Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998; 88:1002-1008.
35. Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005; 62:210-216.
36. Gutt B, Wowra B, Alexandrov R, et al. Gamma-knife surgery is effective in normalising plasma insulin-like growth factor I in patients with acromegaly. Exp Clin Endocrinol Diabetes 2005; 113:219-224.
37. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Endocrinol Metab 2000; 85: 526-529.
38. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004; 151: 317-324.
39. van Thiel SW, Romijn JA, Biermasz NR et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.Eur J Endocrinol 2004; 1
40. Ashwell SG, Bevans JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004; 150: 473-480.
41. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005; 90: 5627-5631.
42. Trainer P. The use of pegvisomant as either monotherapy or combination with octreotide LAR in patients with acromegaly uncontrolled by octreotide LAR - results from a prospective clinical trial. In:9th European Congress of Endocrinology. Budapest, Ungarn, 2007.
43. Kajiwara K, Saito K, Yoshikawa K, et al. Image-guided stereotactic radiosurgery with the CyberKnife for pituitary adenomas. Minim Invasive Neurosurg 2005; 48:91-96.
44. Engenhart-Cabillic R, Kocher M, Muller RP, et al. Leitlinien zur Strahlentherapie von Hypophysenadenomen. Dtsch Med Wochenschr 1999; 124:1148-1152.
45. Petersenn S, Lüdecke DK, Fahlbusch R, et al. Therapie von Hypophysentumoren. Dt Arztebl 2006; 103:A474-481.
46. American Association of Clinical Endocrinologists. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract 2004; 10:213-225.
47. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89:1613-1617.
48. Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998; 88:1002-1008.
49. Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005; 62:210-216.
50. Gutt B, Wowra B, Alexandrov R, et al. Gamma-knife surgery is effective in normalising plasma insulin-like growth factor I in patients with acromegaly. Exp Clin Endocrinol Diabetes 2005; 113:219-224.
51. Bidlingmaier M, Strasburger CJ. Growth hormone assays: current methodologies and their limitations. Pituitary 2007; 10:115-119.
52. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 2007; 67:65-70.
53. Schneider HJ, Saller B, Sievers C, et al. Unexpectidely high prevalence of acromegaly in patients with elevated IGF-1 levels in primary care. 12th Meeting ENEA, Athen, 21.-24.10.06.
54. Neggers SJ, van der Lely AJ. Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat Rev Endocrinol. 2009 Oct;5(10):546-52. Review.
55. Neggers SJ, van Aken MO, Janssen JA, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007 Dec;92(12):4598-601. Epub 2007 Sep 25.
56. Neggers SJ, de Herder WW, Janssen JA, et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol. 2009 Apr;160(4):529-33. Epub 2009 Jan 13.
57. Trainer PJ, Ezzat S, D'Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf). 2009 Oct;71(4):549-57. Epub 2009 May 2.
58. Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008 Oct;93(10):3853-9. Epub 2008 Jul 22.
59. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007 Jan 4;356(1):39-46.